Neuroinflammation may have beneficial or detrimental net effects on the cognitive outcome of Alzheimer's disease (AD) patients. 18kDa translocator protein (TSPO) imaging by positron-emission-tomography (PET) enables longitudinal monitoring of microglial activation in vivo. We compiled serial PET measures of TSPO and amyloid with terminal cognitive assessment (water maze) in an AD transgenic mouse model (PS2APP) from eight to 13 months of age, followed by immunohistochemical analyses of microglia, amyloid and synaptic density. Better cognitive outcome and higher synaptic density in PS2APP mice was predicted by higher TSPO expression at eight months. The progression of TSPO activation to 13 months also showed a moderate association with spared cognition, but amyloidosis did not correlate with the cognitive outcome, regardless of the timepoint. This first PET investigation with longitudinal TSPO-and amyloid-PET together with terminal cognitive testing in an AD mouse model indicates that continuing microglial response seems to impart preserved cognitive performance.
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia, and is placing an ever more onerous burden on health care due to its exponentially rising incidence with increasing age (1) . Immunologically-mediated neuroinflammation is one hallmark of the pathophysiological process of AD (2, 3) . Current models view neuroinflammation as a double-edged sword, which can have protective or detrimental effects on brain pathology, function and the cognitive outcome (4, 5) . Microglia, the resident phagocytes of the innate immune system in the central nervous system continuously survey for pathogens or cellular debris, secrete factors for tissue repair and contribute to plasticity of neuronal circuits by supporting the maintenance and remodeling of synapses (6) .
Microglia in AD brain can recognize and phagocytose soluble and fibrillary β-amyloid (Aβ), resulting in an increased inflammatory reaction (2) . While this kind of acute inflammation response promotes cellular repair and restores brain integrity, chronic inflammation processes can contribute to neurodegeneration (7) .
Various transgenic mouse models of AD recapitulate neuroinflammatory processes in conjunction with classical β-amyloid pathology (8, 9) ; and translational studies of these models are facilitated by small animal positron-emission-tomography (PET) with radioligands for imaging of AD biomarkers (10, 11) . The 18kD translocator protein (TSPO), which is highly expressed at the outer mitrochondrial membrane of activated microglia, presents a valuable biomarker for autoradiographic studies of microglial activation (12, 13) , and likewise for examination by PET of neuroinflammation in brain of AD patients or in AD mouse models (14) .
PET investigation of AD patients indicated only low correlation between cerebral amyloid burden and cognitive performance (15) , and Aβ deposition precedes the onset by E-Library Insel on January 31, 2019. For personal use only. jnm.snmjournals.org Downloaded from of neuroinflammation in patients with mild cognitive impairment (16) . We contend that the temporal sequences of Aβ deposition and microglial activation in relation to progression of cognitive impairments is best examined through molecular imaging studies of longitudinal design. We have established this principle in serial PET examinations of Aβ accumulation in PS2APP mice treated with an experimental γ-secretase inhibitor (17) .
Given this background, we aimed now to correlate serial measures of TSPO-and β-amyloid-PET (Aβ-PET) with the terminal cognitive assessment in the PS2APP amyloid mouse model. Our goals were as follows: (1) Assessment of possible correlations between fibrillar amyloidosis in young and aged PS2APP mice with the cognitive outcome; (2) Determine if early microglial response at baseline has an impact on the terminal cognitive outcome; (3) Determine if ongoing microglial activation influences the terminal cognitive outcome.
MATERIALS AND METHODS

Study Design
All experiments were performed in compliance with the National Guidelines for Animal Protection, Germany, with approval of the local animal care committee of the Government of Oberbayern (Regierung Oberbayern), and overseen by a veterinarian.
The study was performed in a longitudinal design starting with dual tracer PET (TSPO and Aβ) at eight months of age as the first time-point (TP-1). Additional TSPO-PET was acquired at 9.5 months (TP-2), 11.5 months (TP-3) and 13 months (TP-4) of age, while a final Aβ-PET examination was performed at TP-4. After the recovery from the last PET scan, mice were transferred to the behavioral facility and rested for one week before by E-Library Insel on January 31, 2019. For personal use only. jnm.snmjournals.org Downloaded from initiation of the water maze (WM) tests of spatial learning. One week after behavioural test mice were deeply anaesthetized prior to transcardial perfusion. After brain extraction, we processed the brains for immunohistochemical and biochemical analyses (randomized hemispheres). Fig. 1 illustrates the study design.
Insert Fig.1 
Animal Models and Statistical Power Analysis
We used seven female wild-type C57Bl/6 (WT) and ten PS2APP transgenic mice (TG) in this investigation (18, 19) . Required sample sizes were calculated for correlation analyses (TG) and group comparisons (TG vs. WT) using G*power (V3.1.9.2, Kiel, Germany), based on assumptions for a type I error α=0.05 and a power of 0.8. Effect size estimations were based on previous investigations with the same model. One additional animal was included per genotype to account for possible drop-outs.
PET Imaging
PET Acquisition, Reconstruction and Post-Processing: All PET procedures followed an established standardized protocol for radiochemistry, acquisition and post-processing (14, 20) . In brief 18F-GE180 TSPO-PET (11.2±1. 
Water Maze
Mice were subjected to a modified WM task as described previously (22) (23) (24) yielding escape latency and distance to the correct platform as read outs.
Mice had to distinguish between two visible platforms, one of which was weighted in a way that it would float when the mouse climbed on (correct choice), while the other would sink (wrong choice). The correct platform was always located at the same spot in the maze, while the wrong platform as well as the site from which the mice were released into the maze was varied in a pseudorandom fashion. Visual cues on the walls of the laboratory provided orientation. Trials were terminated if the mouse had failed to reach one of the platforms within 30 sec (error of omission). In this case, or in case of a wrong choice, the experimenter placed the mouse on the correct platform. After a threeday handling period, WM training was performed on five consecutive days, with five trials per day, which were conducted 2-4 minutes apart. Memory performance was assessed by measuring the escape latency at each day of training and by the travelled distance at the last training day. For escape latency we calculated the summed average time of all trials from the start point to attaining one of the platforms. To generate as robust values as possible for individual PS2APP mice, we calculated the Z-score difference for both methods in contrast with mean WT mouse scores ((PS2APP -AVGWT) / SDWT) and built a summed Z-score for each mouse. On the sixth day, the right platform was placed in the opposite quadrant of the maze to confirm that the mice had used spatial cues rather than rule-based learning to find it. Trials were filmed with a video camera and the swimming trace was extracted using custom written LabView software (National Instruments). The experimenter was blind accordingly to the phenotype of the animals.
Immunohistochemistry and Biochemistry
Immunohistochemistry in brain regions corresponding to PET was performed for fibrillar Aβ (methoxy-X04), microglia (Iba1), and synaptic density (VGLUT1) as previously established (25, 26) . Assessment of soluble Aβ assessment was performed as previously published (27) . 
RESULTS
Microglial Activity, Amyloidosis and Cognitive Performance in PS2APP Mice
TSPO-PET examination of PS2APP mice indicated an inverted U-shape from eight to 13 months of age with peak at 11.5 months for microglial activation and Aβ-PET showed the expected strong increase of amyloidosis from eight to 13 months of age ( Figs. 2A and 2B ). This increase was most pronounced in the frontal and parietal cortex as well as in the hippocampus and the thalamus. Microgliosis was strongest in the cortex and the hippocampus, but additionally in subcortical regions devoid of Aβ like the striatum, entorhinal and piriform cortices. Behavioral testing by WM showed that PS2APP mice had cognitive impairment, as revealed by increased escape latency (F(1,15)=35.1, p<0.001) and +436% higher travelled distance (p<0.01) compared to WT mice (Fig.2C) . There was no difference in speed between PS2APP and WT mice. 
Prediction of Cognitive Performance by Serial PET Imaging
We undertook longitudinal in vivo observations of amyloidosis and microglial activity by PET to test if early or cumulative alterations over time of the pathology biomarkers predicted the cognitive outcome of PS2APP mice. We find that better cognitive performance is strongly associated with microglial activation five months earlier in forebrain (R=-0.71, P<0.05; Fig. 4A ) and especially in cognition-associated areas (R=-0.82, P<0.01; Fig. 4B ). Peak clusters of the amygdala, the entorhinal cortex, and the hippocampus as identified by SPM, gave especially strong regional correlations of high earlier microglial activity and better cognitive performance (R=-0.95, P<0.001; Fig. 4C ).
Statistical maps of the correlation between voxelwise microglial activity and WM performance revealed a pattern with strongest association in brain areas involved in spatial learning networks, i.e. the hippocampal formation, the thalamus, and the frontal neocortex (28) (Fig. 4D ). There were no brain regions showing a negative correlation between TSPO-PET at baseline and better terminal cognitive performance. Insert Fig.4 We had predicted an opposite relationship for cumulative TSPO-PET values over time during the whole five months imaging period, since chronic activation of microglia could damage synapses, leading to neurodegeneration (7). However, we still observed the same positive correlation, meaning that high AUCs of microglial activity were associated with a better cognitive performance (Supplemental Figs. 1A-C) . Correlations between AUCs of microglial activity and WM performance were weaker when compared to TSPO-PET findings at baseline, but the spatial pattern of regions related to spatial learning networks was even better demarcated (Supplemental Fig. 1D ). No brain region indicated a significant association between lower longitudinal AUCs of microglial activation and better terminal cognitive performance. There were no relevant associations of the Aβ-PET signal at baseline or by longitudinal AUC analysis of amyloidosis with the terminal cognitive performance.
Finally, we asked if there is a molecular correlate of the associations between microglial activation over time and the terminal cognitive performance. Our terminal immunohistochemical analyses of synaptic density showed clear reductions of VGLUT1 in the dentate gyrus and the frontal cortex of PS2APP mice when compared to WT at 14 months of age (Fig. 5A) . Reductions of VGLUT1 in individual PS2APP mice had a moderately strong correlation with behavioral assessment of cognition ( Fig. 5B ; R=-0.53; p=0.12 each). Even more importantly, we also observed that baseline TSPO-PET predicted synaptic density measured five months later in the dentate gyrus (R=0.71; p<0.05) and the frontal cortex (R=0.57; p<0.1; Fig. 5B and 5C ). Thus, we find that an early microglial response to amyloid pathology in PS2APP TG mice protects synaptic density at follow-up. an early and ongoing microglial response. We also saw some evidence for an association between more pronounced stronger terminal neuroinflammation at 14 months and better preservation of cognitive function (Fig. 2) . At first glance, our findings seem at odds with findings of neuronal dysfunction arising from exposure of neurons to pro-inflammatory mediators during chronic microglial activation (7). However, not all microglia are equal, and it remains a question about specifically what activation state of microglia an elevated TSPO-PET signal or Iba1 immunohistochemistry actually reveals.
There are some hints that elevated TSPO expression is associated with a CD86-positive pro-inflammatory microglia phenotype (32) . Nonetheless, the authors of that study also observed co-localization of TSPO immunostaining with CD206-positive antiinflammatory microglia near amyloid plaques, which could indicate microglial phagocytosis of toxic Aβ (33) . Clearance of accumulating debris like misfolded proteins is indeed a crucial function of anti-inflammatory microglia in their role of protecting brain tissue homeostasis (7) . Interventional studies with, for example, PPARγ agonists to modify microglial phenotype, along with serial microglia monitoring and behavioral testing, might address this question in more detail (34) . From the current data, it emerges that early microglial activation ameliorates the cognitive decline in PS2APP mice (Fig. 3) . Thus, it seems an essential aspect of the innate immune system that it can respond to the developing amyloidosis caused by the genetic modification of the mouse model. The net beneficial effect of longitudinal microglial activation on cognitive function might be a matter of duration, as synapses will ultimately suffer from excessive exposure to pro-inflammatory cytokines. Thus, present protective effect of elevated microglial activity on cognitive function in PS2APP mice might have turned into deterioration at times after 14 months.
Another possible explanation for contradictory findings in studies on neuroinflammation and subsequent cognitive outcome might be attributable to differing mechanistic approaches. Most such investigations used mice with specific manipulations of genes involved in inflammatory pathways of AD and tested against WT data. We took advantage of the known phenotype heterogeneity of the PS2APP mouse (35) to study associations of biomarkers and the terminal cognitive performance in individual mice of the same genotype. Our findings imply that a strong magnitude of microglial activation is probably necessary to cope with the characteristically heavy Aβ deposition in these mice (14) . This conception fits our current findings of preserved cognitive performance in mice with an early microglial response. As an explanation for this phenomenon, we invoke the recent description of two peaks of microglial activation in the time course of human sporadic AD, one occurring in the pre-symptomatic stage during early amyloid build-up and the other presenting in the dementia stage (36) . Amyloid mouse models have little neuronal loss, and more closely mimic primarily pre-symptomatic and mild-cognitiveimpairment stages of human AD (27) . Taken together, our preclinical data support the speculation of an early protective peak of microglial activation during initial amyloid aggregation (36) . Since PS2APP mice show their peak of microglial activation at approximately 11.5 months (Fig. 1) , we speculate that they may lack a second peak, as they do not show much progression of neuronal loss even at very late stages >16 months of age (18) . we have generated 3-dimensional maps of microglial activity over time in individual mice (AUC maps), and used these maps for a statistically-based voxel-wise correlation analysis with cognitive outcome parameters. Statistical testing of SPM-defined regions should be interpreted with care, but our analyses also clearly showed an enhanced association between PET measures of microgliosis in predefined brain regions linked to spatial learning with preserved cognition (28) . This methodological innovation provides the basis for designing intervention studies with endpoints relevant to human AD.
CONCLUSION
Early microglial response predicts an improved cognitive outcome in PS2APP mice, whereas the magnitude of fibrillar amyloidosis in early disease stages is not predictive of cognitive performance five months later. These findings emphasize the importance of biomarkers for serial monitoring of microglial activity in AD. Furthermore, results suggest than the innate immune system could constitute a more relevant therapeutic target than amyloidosis regarding the primary objective of preserving cognitive performance. Figures   Fig.1 : Schematic illustration of the study design and timeline. We obtained a series of dual tracer PET scans (TSPO and Aβ) in mice between 8 and 13 months of age. After the final scan, we administered behavioural testing by the water maze (WM), followed by transcardial perfusion with 4% paraformaldehyde and brain extraction for histochemical, immunohistochemical and biochemical analyses.
